Karyopharm Therapeutics (KPTI) Key Ratios

$0.61

up-down-arrow $-0.04 (-5.43%)

As on 08-Oct-2026 10:37EDT

Market cap

info icon

$18 Mln

Revenue (TTM)

info icon

$147 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

12

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -4.66 -11.86 6.81 0.14 7.47
EBIT -447.66 -107.35 -123.46 -20.35 0.81
Net Profit -199.32 -79.92 -81.88 -25.55 -1.67
EPS -155.64 46.41 13.37 8.84 10.20
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -70.35-69.35-120.04-102.79-26.81
Net Margin info ---81.36-153.28----
Return on equity info 105.51302.35--81.8647.43
Return on Capital info 106.9620.77--771.62-309.92
Return on Assets info -76.42-63.85-99.96-143.71-37.75
Debt to Equity (x) info -----0.63-0.80-1.05
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
771.62
-309.92
-140.83
-125.54
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
81.86
47.43
187.23
343.18
Peer Median
-39.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-99.96

Lower than Peers by 68.77

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-99.96
-143.71
-37.75
-47.81
-49.83
Peer Median
-31.19
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-120.04

Lower than Peers by 43.51

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-120.04
-102.79
-26.81
-81.46
-89.08
Peer Median
-76.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-153.28

Lower than Peers by 67.71

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-153.28
-134.21
-52.62
-97.99
-103.73
Peer Median
-85.56
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

6.81

Lower than Peers by 47.81

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
6.81
0.01
-0.01
-0.07
-0.25
Peer Median
54.63
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-123.46

Lower than Peers by 122.08

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-123.46
-285.56
67.26
14.99
-43.11
Peer Median
-1.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-81.88

Lower than Peers by 75.08

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-81.88
-156.52
46.60
13.43
-33.20
Peer Median
-6.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

13.37

Lower than Peers by 0.76

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
13.37
-0.18
0.51
0.32
-0.29
Peer Median
14.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

58.84

Higher than Peers by 68.33

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
58.84
--
--
--
--
Peer Median
-9.50
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

-0.63

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-0.63
-0.80
-1.05
-1.30
-10.75
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
0.00
-0.08
-0.13
-0.02
-0.17
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.79

Lower than Peers by 5.04

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
0.79
1.12
1.70
3.37
5.31
Peer Median
5.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.76

Lower than Peers by 4.94

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
0.76
1.08
1.64
3.32
5.25
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-3.56

Lower than Peers by 1.41

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-3.56
-3.27
-1.04
-4.99
-5.60
Peer Median
-2.15
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

20.37

Higher than Peers by 1.32

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
20.37
17.92
21.18
18.46
29.98
Peer Median
19.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.65

Higher than Peers by 0.59

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
0.65
1.07
0.72
0.49
0.47
Peer Median
0.07
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
71.20
72.59
92.60
80.90
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
269.44
236.59
268.54
291.82
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
279.66
250.21
217.88
153.30
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
60.97
58.97
143.27
219.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
-0.68
-0.07
-0.05
-0.12
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

12.05

Higher than Peers by 7.57

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
12.05
-0.46
-0.03
-0.05
-1.22
Peer Median
4.48
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-1.85

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
-1.85
-2.03
-2.37
0.07
0.56
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

18

Lower than Peers by 123

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Karyopharm Therapeutics (KPTI)
18
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...